Cope Andrew P, Barnes Michael R, Belson Alexandra, Binks Michael, Brockbank Sarah, Bonachela-Capdevila Francisco, Carini Claudio, Fisher Benjamin A, Goodyear Carl S, Emery Paul, Ehrenstein Michael R, Gozzard Neil, Harris Ray, Hollis Sally, Keidel Sarah, Levesque Marc, Lindholm Catharina, McDermott Michael F, McInnes Iain B, Mela Christopher M, Parker Gerry, Read Simon, Pedersen Ayako Wakatsuki, Ponchel Frederique, Porter Duncan, Rao Ravi, Rowe Anthony, Schulz-Knappe Peter, Sleeman Matthew A, Symmons Deborah, Taylor Peter C, Tom Brian, Tsuji Wayne, Verbeeck Denny, Isaacs John D
Centre for Inflammation Biology and Cancer Immunology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Great Maze Pond, London, SE1 1UL, UK.
Queen Mary University of London, UK.
Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7.
Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of 'big data'. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.
合作可能具有挑战性；然而，生物医学领域大型、多伙伴、跨国合作组织和研究网络不断涌现的成功案例，持续激发了学术界和行业伙伴开发和培育新研究联盟的兴趣。这种模式已渗透到全球各国的资助机构，促使它们为旨在实现21世纪基因组医学真正潜力并收获“大数据”回报的项目提供资金。在这篇观点文章中，描述了RA-MAP联盟的经验，该联盟由来自21个学术和行业组织的140多名成员组成，致力于将类风湿性关节炎的基因组医学变为现实。文中强调了英国多伙伴合作面临的挑战，并提供了一系列广泛的解决方案，这些方案可能会让全球大型研究联盟受益。
